A 52 year old man with myasthenia gravis and normal liver function was treated with neostigmine, prednisolone and azathioprine. Three years after starting azathioprine he developed clinical evidence of portal hypertension. A liver biopsy showed nodular regenerative hyperplasia (NRH).
Introduction
Portal hypertension association with nodular regenerative hyperplasia of the liver (NRH) secondary to immunosuppressive therapy has been previously described, usually after renal transplantation. 1 Over the next 2 years his myasthenia improved and he remained in good general health. His MCV rose to 115 fl and platelet count fell to 110 x 109/1. These changes were considered to be the result of azathioprine therapy.
Three years after starting azathioprine the spleen was found to be enlarged 4cm in the mid clavicular line below the costal margin, on routine physical examination. He had no other symptoms or signs suggestive of liver disease. Investigations: haemoglobin 12.1 g/dl, white cell count 3.4 x 109/l, MCV 113 fl, platelets 103 x 109/1; urea 4.3 mmol/l, bilirubin 70,mol/l; AST 40 U/1; ALP 107 U/1; gamma glutamyl transferase (GGT) 125 U/I (10-48); amylase 85 U/I (0-220). Ultrasound: small liver, portal vein and splenic vein enlarged. Spleen grossly enlarged with several prominent vessels around the hilum. Liver biopsy (3 cylinders each 1 cm) showed nodular regenerative hyperplasia, characterized by small hyperplastic nodules with intervening atrophy but no substantial degree of fibrosis (see Figure 1) .
Azathioprine was stopped and cyclophosphamide commenced but he developed haemorrhagic cystitis and cyclophosphamide had to be discontinued. Six months after discontinuation of azathioprine splenomegaly persists but his MCV has fallen to 
Discussion
The development of portal hypertension in this patient appears to be related to treatment with azathioprine. Biopsy confirmed that the increased portal venous pressure was associated with nodular regenerative hyperplasia.
Hepatic dysfunction is not uncommon in patients treated with azathioprine. This usually manifests as a reversible acute cholestatic hepatitis4 or occasionally as acute focal hepatocellular necrosis5 or venoocclusive disease.6 Nodular regenerative hyperplasia leading to portal hypertension has previously been described in patients taking azathioprinel' 2 but most of the patients described were on another immunosuppressive therapy as well. The largest proportion of patients with this complication have had renal transplantation.' As renal disease and transplantation is associated with an increased incidence of vascular events, azathioprine, while suspected of being the cause of liver changes, could not be conclusively incriminated. Myasthenia gravis is not associated with recorded increased risk of occlusive vascular disease, nor are treatment with steroids and neostigmine. Azathioprine therefore is likely to be the sole agent responsible for the development of portal hypertension in this patient and strengthens the case for a causal role of azathioprine in producing these effects.
